During the last session, Lucid Diagnostics Inc. (NASDAQ:LUCD)’s traded shares were 0.15 million. At the end of the trading day, the stock’s price was $3.36, reflecting an intraday gain of 5.99% or $0.19. The 52-week high for the LUCD share is $13.52, that puts it down -302.38 from that peak though still a striking 49.7% gain since the share price plummeted to a 52-week low of $1.69. The company’s market capitalization is $129.02M, and the average intraday trading volume over the past 10 days was 0.11 million shares, and the average trade volume was 102.84K shares over the past three months.
Lucid Diagnostics Inc. (LUCD) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.60. LUCD has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.33.
Lucid Diagnostics Inc. (NASDAQ:LUCD) trade information
Lucid Diagnostics Inc. (LUCD) registered a 5.99% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.99% in intraday trading to $3.36 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 14.68%, and it has moved by 28.24% in 30 days. The short interest in Lucid Diagnostics Inc. (NASDAQ:LUCD) is 0.29 million shares and it means that shorts have 2.83 day(s) to cover.
The consensus price target of analysts on Wall Street is $8.00, which implies an increase of 58.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5.00 and $13.00 respectively. As a result, LUCD is trading at a discount of -286.9% off the target high and -48.81% off the low.
Lucid Diagnostics Inc. (LUCD) estimates and forecasts
Statistics show that Lucid Diagnostics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Lucid Diagnostics Inc. (LUCD) shares have gone up 5.66% during the last six months, with a year-to-date growth rate more than the industry average at 5.96% against 2.60. In the rating firms’ projections, revenue will increase 860.00% compared to the previous financial year.
Revenue for the current quarter is expected to be $640k as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $1.39 million by the end of Sep 2022.
While earnings are projected to return -259.30% in 2022.
Lucid Diagnostics Inc. is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lucid Diagnostics Inc. (NASDAQ:LUCD)’s Major holders
Lucid Diagnostics Inc. insiders own 78.14% of total outstanding shares while institutional holders control 7.04%, with the float percentage being 32.21%. Luminus Management, LLC is the largest shareholder of the company, while 53 institutions own stock in it. As of Mar 30, 2022, the company held over 0.76 million shares (or 1.99% of all shares), a total value of $2.54 million in shares.
The next largest institutional holding, with 0.33 million shares, is of Cantor Fitzgerald, L. P.’s that is approximately 0.88% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $1.12 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lucid Diagnostics Inc. (LUCD) shares are Vanguard Total Stock Market Index Fund and Putnam Fds Tr-Putnam Multi Cap Core Fd. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 0.29 million shares. This amounts to just over 0.75 percent of the company’s overall shares, with a $0.96 million market value. The same data shows that the other fund manager holds slightly less at 0.23 million, or about 0.61% of the stock, which is worth about $0.49 million.